These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11335721)

  • 1. Crystallographic approach to identification of cyclin-dependent kinase 4 (CDK4)-specific inhibitors by using CDK4 mimic CDK2 protein.
    Ikuta M; Kamata K; Fukasawa K; Honma T; Machida T; Hirai H; Suzuki-Takahashi I; Hayama T; Nishimura S
    J Biol Chem; 2001 Jul; 276(29):27548-54. PubMed ID: 11335721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loop flexibility and solvent dynamics as determinants for the selective inhibition of cyclin-dependent kinase 4: comparative molecular dynamics simulation studies of CDK2 and CDK4.
    Park H; Yeom MS; Lee S
    Chembiochem; 2004 Dec; 5(12):1662-72. PubMed ID: 15505811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.
    Honma T; Yoshizumi T; Hashimoto N; Hayashi K; Kawanishi N; Fukasawa K; Takaki T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Hayama T; Nishimura S; Morishima H
    J Med Chem; 2001 Dec; 44(26):4628-40. PubMed ID: 11741480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors.
    McInnes C; Wang S; Anderson S; O'Boyle J; Jackson W; Kontopidis G; Meades C; Mezna M; Thomas M; Wood G; Lane DP; Fischer PM
    Chem Biol; 2004 Apr; 11(4):525-34. PubMed ID: 15123247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Understanding and modulating cyclin-dependent kinase inhibitor specificity: molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors.
    Rossi KA; Markwalder JA; Seitz SP; Chang CH; Cox S; Boisclair MD; Brizuela L; Brenner SL; Stouten PF
    J Comput Aided Mol Des; 2005 Feb; 19(2):111-22. PubMed ID: 16075305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4.
    Blain SW; Montalvo E; Massagué J
    J Biol Chem; 1997 Oct; 272(41):25863-72. PubMed ID: 9325318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based generation of a new class of potent Cdk4 inhibitors: new de novo design strategy and library design.
    Honma T; Hayashi K; Aoyama T; Hashimoto N; Machida T; Fukasawa K; Iwama T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Iwasawa Y; Hayama T; Nishimura S; Morishima H
    J Med Chem; 2001 Dec; 44(26):4615-27. PubMed ID: 11741479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pyrido[2,3-d]pyrimidin-7-one inhibitors of cyclin-dependent kinases.
    Barvian M; Boschelli DH; Cossrow J; Dobrusin E; Fattaey A; Fritsch A; Fry D; Harvey P; Keller P; Garrett M; La F; Leopold W; McNamara D; Quin M; Trumpp-Kallmeyer S; Toogood P; Wu Z; Zhang E
    J Med Chem; 2000 Nov; 43(24):4606-16. PubMed ID: 11101352
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structural analysis of the inhibition of Cdk4 and Cdk6 by p16(INK4a) through molecular dynamics simulations.
    Villacañas O; Pérez JJ; Rubio-Martínez J
    J Biomol Struct Dyn; 2002 Dec; 20(3):347-58. PubMed ID: 12437373
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
    Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
    Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Removal of Cdk inhibitors through both sequestration and downregulation in zearalenone-treated MCF-7 breast cancer cells.
    Ahamed S; Foster JS; Bukovsky A; Diehl JA; Wimalasena J
    Mol Carcinog; 2002 May; 34(1):45-58. PubMed ID: 12112322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The p16 status of tumor cell lines identifies small molecule inhibitors specific for cyclin-dependent kinase 4.
    Kubo A; Nakagawa K; Varma RK; Conrad NK; Cheng JQ; Lee WC; Testa JR; Johnson BE; Kaye FJ; Kelley MJ
    Clin Cancer Res; 1999 Dec; 5(12):4279-86. PubMed ID: 10632371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity.
    Calbó J; Serna C; Garriga J; Graña X; Mazo A
    Cell Death Differ; 2004 Oct; 11(10):1055-65. PubMed ID: 15309028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-induced activation of Cdk4 and Cdk2 during G1-S phase progression is accompanied by increased cyclin D1 expression and decreased cyclin-dependent kinase inhibitor association with cyclin E-Cdk2.
    Prall OW; Sarcevic B; Musgrove EA; Watts CK; Sutherland RL
    J Biol Chem; 1997 Apr; 272(16):10882-94. PubMed ID: 9099745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
    Hirai H; Kawanishi N; Iwasawa Y
    Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural basis of inhibition of CDK-cyclin complexes by INK4 inhibitors.
    Jeffrey PD; Tong L; Pavletich NP
    Genes Dev; 2000 Dec; 14(24):3115-25. PubMed ID: 11124804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00.
    Joshi KS; Rathos MJ; Joshi RD; Sivakumar M; Mascarenhas M; Kamble S; Lal B; Sharma S
    Mol Cancer Ther; 2007 Mar; 6(3):918-25. PubMed ID: 17363486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisation.
    Anderson M; Beattie JF; Breault GA; Breed J; Byth KF; Culshaw JD; Ellston RP; Green S; Minshull CA; Norman RA; Pauptit RA; Stanway J; Thomas AP; Jewsbury PJ
    Bioorg Med Chem Lett; 2003 Sep; 13(18):3021-6. PubMed ID: 12941325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of cdk4 and cdk2 during rat liver regeneration is associated with intranuclear rearrangements of cyclin-cdk complexes.
    Jaumot M; Estanyol JM; Serratosa J; Agell N; Bachs O
    Hepatology; 1999 Feb; 29(2):385-95. PubMed ID: 9918914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
    Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
    Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.